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Abstract
Background: Emerging epidemiological evidence suggests that statins may reduce the risk of community-acquired
pneumonia (CAP) and its complications.
Purpose: Performed a systematic review to address the role of statins in the prevention or treatment of CAP.
Data Source: Ovid MEDLINE, Cochrane, EMBASE, ISI Web of Science, and Scopus from inception through December 2011
were searched for randomized clinical trials, cohort and case-control studies.
Study Selection: Two authors independently reviewed studies that examined the role of statins in CAP.
Data Extraction: Data about study characteristics, adjusted effect-estimates and quality characteristics was extracted.
Data Synthesis: Eighteen studies corresponding to 21 effect-estimates (eight and 13 of which addressed the preventive and
therapeutic roles of statins, respectively) were included. All studies were of good methodological quality. Random-effects
meta-analyses of adjusted effect-estimates were used. Statins were associated with a lower risk of CAP, 0.84 (95% CI, 0.74–
0.95), I2 = 90.5% and a lower short-term mortality in patients with CAP, 0.68 (95% CI, 0.59–0.78), I2 = 75.7%. Meta-regression
did not identify sources of heterogeneity. A funnel plot suggested publication bias in the treatment group, which was
adjusted by a novel regression method with a resultant effect-estimate of 0.85 (95% CI, 0.77–0.93). Sensitivity analyses using
the rule-out approach showed that it is unlikely that the results were due to an unmeasured confounder.
Conclusions: Our meta-analysis reveals a beneficial role of statins for the risk of development and mortality associated with
CAP. However, the results constitute very low quality evidence as per the GRADE framework due to observational study
design, heterogeneity and publication bias.
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Introduction
The incidence of community-acquired pneumonia (CAP) ranges
between 3 and 40 per 1000 inhabitants per year with estimated
rates of hospitalization and overall mortality of 40–60% and 10%,
respectively [1]. Despite advances in antimicrobial therapy the
mortality from CAP has remained relatively constant [2]. CAP has
been associated with both short-term (within 30–90 days after
CAP) [3] and increased long-term mortality [4–5]. In view of its
common occurrence, an aging population and rising healthcare
costs, CAP presents a major problem and is one of the leading
causes of death [6]. Therefore, besides anti-microbial therapy
other potential approaches should be considered for a better
outcome of CAP.
Several factors have been postulated for the adverse outcomes in
CAP including acute lung injury (ALI), vascular dysfunction and
coagulopathy due to a dysregulated inflammatory response caused
by invading microorganisms. The pathogenesis of ALI and acute
respiratory distress syndrome (ARDS) includes a ‘cytokine storm’,
which is involved in the initiation and amplification of these
syndromes [7]. Several studies have reported that an excessive
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inflammatory response and increased inflammatory markers
predict adverse outcomes in pneumonia secondary to sepsis, lung
injury and ARDS [8–11]. There are supportive data to suggest
that 30-day mortality in patients with pneumonia is directly caused
by pneumonia rather than due to co morbid conditions [3–4].
Statins have pleiotropic effects – immunomodulatory [12], anti-
inflammatory, anti-thrombotic [13] and a direct microbicidal
action [14]; all of which may have potential beneficial role in the
prevention and treatment of CAP.
Patients with pneumonia also are at increased risk for cardiac
events secondary to increased inflammatory cytokines which could
lead to increased thrombosis [15–16], interfere with endothelial
and ventricular function [17–18], cause instability of plaques [19]
and promote reperfusion injury [20]. Observational studies have
reported increased cardiovascular outcomes in patients with
pneumonia [21–25]. The proposed beneficial effect of statins in
diminishing the risk of cardiac events is due to their anti-
inflammatory effect, rather than due to their lipid-lowering
properties [26]. Recently, three meta-analyses have shown
beneficial roles of statins in the prevention and treatment of
several different types of infections [27–29].
There have been a number of observational studies evaluating
the role of statins in the prevention and treatment of pneumonia
[30–47]. A recently published meta-analysis did not find an
association between the use of statins and prevention of
pneumonia when using unadjusted data; but did find an
association using adjusted data. This reveals the significance of
potential confounders in this association [48]. Another recent
meta-analysis suggested a beneficial role of statins in the
management of pneumonia [49]. Nevertheless, this review had
important limitations, namely ignoring the significant between-
study heterogeneity, and publication bias and thus, overestimating
the true association.
Another recent meta-analysis of randomized controlled trials
(RCT) has also suggested unmeasured confounding as one of the
reasons for the apparent beneficial effect of statins in the context of
infections [50]. Currently, there are no RCT addressing the role of
statins in CAP (www.clinicaltrials.gov).
Given this ongoing controversy, we performed a contemporary
systematic review and meta-analysis that addressed the role of
statins in the prevention or treatment of CAP and used novel
methodology. We added unique approaches to adjust for
publication bias as well as explored the potential effect of
unknown confounders. We used the Grades of Recommendation,
Assessment, Development and Evaluation (GRADE) framework to
interpret our findings [51].
Methods
Data Sources and Search Strategy
The systematic review was carried out in accordance to the
meta-analysis of observational studies in epidemiology and
preferred reporting items for systematic reviews and meta-analyses
guidelines [52–53].
The search strategies were developed in Ovid MEDLINE, and
translated to match the subject headings and keywords for Ovid
EMBASE, Cochrane database, ISI Web of Science, and Scopus
from database inception through December 5, 2011. The subject
heading hydroxyl-methyl-glutaryl-CoA reductase inhibitors, in-
cluding more specific statin subject headings, and keywords for the
specific statins: hmgadjcoa or atorvastatin or cerivastatin or
compactin or dalvastatin or fluindostation or lovastatin or
mevinolin* or monacolin* or pitavastatin or pravastatin or
rosuvastatin or simvastatin were matched to subject headings for
all respiratory tract infections, pneumonia, CAP, lower respiratory
tract infections and chronic obstructive pulmonary disease. There
was no restriction of language. All results were downloaded into
EndNote 7.0 (Thompson ISI ResearchSoft, Philadelphia), a
bibliographic database manager, and duplicate citations were
identified and removed. Two authors (A.R.K & A.B.A) indepen-
dently assessed the eligibility of identified studies.
Study Selection
The results that were further evaluated were limited to clinical
trials, observational studies, case series, and any study that focused
on association of statin use and prevention, or prophylaxis, or
outcome of CAP and reported an adjusted effect-estimate for this
association. Published abstracts or unpublished data was not
included as it has been reported that there is discrepancy between
published and unpublished data [54–55].
We did not specify a priori CAP definition or statins use and
they were accepted as defined in individual studies. The outcome
was either the incidence of CAP or all cause mortality within the
stipulated period of time after an index episode of CAP.
Data Extraction
Two reviewers (A.R.K. and A.B.A.) independently extracted
data on a predefined data collection form. Disagreements between
reviewers that could not be resolved by consensus were resolved by
a third reviewer (I.M.T).
Extracted data included the following: geographical population
under study, subject characteristics, statins intake definition and
ascertainment, outcome definitions for prevention and treatment
studies and adjusted effect-estimates based on analytical model
used in each study. In studies which had multiple adjustments for
effect-estimate, the final composite adjusted effect-estimate was
used. Since we have focused our analysis on adjusted estimates, we
did not attempt to get subgroup data from authors as these data
are biased by confounding.
Quality Assessment
Two reviewers (M.A.G. and A.R.K) independently assessed the
methodological quality of selected studies using the Newcastle-
Ottawa Quality Assessment Scale for cohort and case-control
studies. This scale is used to explore selection bias and
comparability between the exposed and unexposed groups,
outcome assessment, and attrition bias [56]. Disagreements
between reviewers that could not be resolved by consensus were
resolved by a third reviewer (I.M.T).
We used the GRADE framework to interpret our findings. The
Cochrane Collaboration has adopted the principles of the
GRADE system for evaluating the quality of evidence for
outcomes reported in systematic reviews [51]. For purposes of
systematic reviews, the GRADE approach defines the quality of a
body of evidence as the extent to which one can be confident that
an estimate of effect or association is close to the quantity of
specific interest. Quality of a body of evidence involves consider-
ation of within-study risk of bias (methodological quality),
directness of evidence, heterogeneity, precision of effect-estimates
and risk of publication bias [51].
Data Synthesis and Statistical Analysis
The effect-estimates of prevention and treatment studies were
pooled separately using the DerSimonian-Laird random-effects
model [57] with corresponding Forest plots.
Cochran’s Q test was used to assess heterogeneity among
studies, and was complemented by the I2 statistic [58]. The
Role of Statins in Management of Pneumonia
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influence of a range of study-level and aggregated individual-level
parameters on the observed statin effect was investigated by means
of meta-regression. Seven potential confounders were considered;
five categorical that included geographical population under study
(North America vs. European), setting (general practices vs.
others), study design (case control vs. cohort), age of the patient
(,65 vs. all others), industry sponsored (yes/no or undisclosed)
and two continuous variable that included the impact factor of the
journal in which the study was published and log of the standard
error of the effect-estimate.
Publication Bias
Contour-enhanced funnel plots [59] were constructed and
Egger’s precision test (weighted linear regression) [60] was done to
assess funnel plot asymmetry and publication bias. A novel method
of regression adjustment of publication bias was used [61]. This
model consistently outperforms the conventional ‘trim and fill’
method. For the comparison, the Trim and Fill [62] adjusted
effect-estimate was added to the enhanced contour funnel plot.
Residual Confounding
The possible influence of unknown confounders (residual
confounding) was investigated by a novel rule-out approach
[63]. This approach stipulates the influence of a hypothetical
confounder and determines what characteristics this confounder
must have to fully account for the observed association between
statin use and the outcome of interest. The hypothetical
confounder is characterized by its association to statin use (OREC,
odds ratio of exposure to the confounder) and its association to the
outcome (RRCO, relative risk of outcome in individuals exposed to
the confounder). For this analysis, the absolute risk in the pooled,
non-exposed group was used for conversion of odds ratio to
relative risk using the method described by Zhang and Yu [64].
Separate analyses were performed to demonstrate what levels of
OREC and RRCO would be required to fully explain the observed
association between statins and outcome for different hypothetical
prevalence of the unknown confounder (PC = 0.2, PC = 0.5) before
and after adjustment for publication bias.
All analyses were conducted using Stata version 12 statistical
software (StataCorp, Texas).
Results
Identification of Studies
The literature search identified 502 publications, out of which
18 were eligible for inclusion in the analysis [30–47] (Figure 1).
Two studies had both prevention and treatment arms and were
included in both the prevention and the treatment groups [36–37]
and one article comprised of a cohort study and a case-control
study [38] and was considered as two studies. One study [40] did
not distinguish the cause of death, but was included in the analysis
as previous studies have reported that the 30-day mortality is
primarily due to CAP rather than other causes [3–4]. The only
trial on simvastatin in CAP has been suspended for unspecified
reasons [65].
Therefore, a total of 18 studies with 21 effect-estimates were
included in the final analysis. These studies were divided into two
groups; eight studies addressed the role of statins in development
of pneumonia [30–37]; while thirteen studies addressed the role of
statins in outcome of pneumonia [36–47] (Supporting Information
- Table S1: prevention and treatment groups).
Quality assessment of all included cohort and case-control
studies revealed that the studies were of good methodological
quality (Supporting Information - Tables S6–S7).
There was excellent agreement for the inclusion of the studies,
data abstraction and quality assessment between the reviewers
(kappa statistic being 1.0, 1.0 and 0.91 respectively).
Prevention Group
Study characteristics. Supporting Information - Table S1
summarizes the characteristics of the 8 (5 case-control; 3 cohort)
studies included in the prevention group [30–37]. The studies
were conducted in the United Kingdom [31–36], United States
[30] and Canada [37]. Seven were multi-center [31–37]. All of the
included studies were population-based and the majority included
general practice databases. The relevant outcome of interest in all
studies was the development of pneumonia (Supporting Informa-
tion - Table S2). The effect-estimates of included studies had been
adjusted for various confounders (Supporting Information - Table
S3).
Meta-analysis. A random-effects model was used for the
meta-analysis due to substantial between-study heterogeneity
(Cochran Q test, p,0.000; I2 = 90.5%). It resulted in a pooled
effect-estimate of 0.84 (95% CI, 0.74–0.95), suggesting a protective
effect of statins against the development of CAP (Figure 2, left
panel).
There was visual asymmetry in the contour funnel plot but the
number of studies was small, (Supporting Information - Figure S1),
and the Egger’s test did not show evidence of publication bias
(t =21.65, p = 0.160).
The univariate meta-regression analyses showed that none of
the considered variables were significantly related to the effect-
estimate at 5% level of significance.
Adjustment for residual confounding. Sensitivity analysis
to explain the potential effect of residual confounding was
evaluated using the apparent relative risk (ARR = 0.85) of statin
users vs. non-users to prevent CAP. At the prevalence of
(PC = 0.20), even a very strong confounder causing a 99.9%
decrease in CAP risk would have to be severely imbalanced
between statin users vs. non-users (OREC = 1.90) to fully account
for the observed RR of 0.85 (Figure 3, left top panel). The top
right panel for the figure 3 illustrates the same relationship for a
very common confounder (PC = 0.50).
Number Needed to Treat (NNT). The number needed to
treat (NNT) was estimated by using the pooled OR from the meta-
analysis and based on the incidence of CAP ranging from 3–40/
1000 population [1]. The NNT would be 2089 (95% CI; 1285–
6686) and 162 (95% CI; 100–520) for an incidence of CAP to
40 per 1000/year, respectively [3].
Treatment Group
Study characteristics. Supporting Information - Table S1
summarizes the characteristics of the 13 studies (one case-control;
12 twelve cohort) included in the treatment group [36–47]. The
studies were conducted in the United States [38–40,46–47] United
Kingdom [36,43–45], Canada [37,42] and Denmark [41]. Eleven
of them were multi-center [36–38,40–42,44–47]. Statin use was
ascertained by review of computerized medical records or
pharmacy databases. The relevant outcome of interest was
mortality after the diagnosis of pneumonia (either in-hospital or
within a stipulated period of time). Most of the studies reported
either in-hospital or 30 day mortality except Yende et al [46] who
reported a 90 day mortality and Douglas and colleagues who
reported a 6 month mortality [45] (Supporting Information -
Table S4).
The effect-estimates of the included studies had been adjusted
for various confounders (Supporting Information - Table S5).
Role of Statins in Management of Pneumonia
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Meta-analysis. A random-effects model yielded a pooled
effect-estimate of 0.68 (95% CI, 0.59–0.78), suggesting that statin
use was significantly associated with reduced mortality in patients
with CAP. There was substantial between-study heterogeneity
(Cochran Q test, p,0.000 and I2 = 75.7%) (Figure 2, right panel).
The univariate meta-regression analyses showed that the
variable ‘‘standard error of the effect-estimate’’ among the
considered variables for meta-regression was significantly related
to the effect-estimate at 5% level of significance. This suggests a
stronger association between statin use and risk of CAP in studies
with large standard errors.
Figure 4 displays a contour-enhanced funnel plot with the
corresponding fixed effect (FE) and random effect (RE) meta-
analyses pooled estimates providing a weighted average of effect
size across studies of 0.81 (95% CI, 0.78–0.85) and 0.68 (0.59–
0.78), respectively. There was visual evidence of funnel asymmetry
Figure 1. Flow diagram of eligible studies.
doi:10.1371/journal.pone.0052929.g001
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and Egger’s test confirms the presence of publication bias,
P = 0.014. Hence, a novel regression based method was used to
adjust for publication bias (Figure 4). This produced an adjusted
average effect-estimate of 0.80 (95% CI, 0.66–0.96).
Adjustment for residual confounding. Sensitivity analysis
to explore the potential effect of residual confounding was
evaluated using the apparent relative risk of statin users vs. non-
users, before (ARR = 0.7) and after adjustment for publication bias
(ARR = 0.80). At the prevalence of (PC = 0.20) even a very strong
confounder causing a 99.9% decrease in mortality would have to
be highly imbalanced between statin users vs. non-users
(OREC = 3.21) to fully account for the observed RR of 0.70
(Figure 3, bottom left panel). Similarly Figure 3, bottom right
Panel illustrates the relationship for a very common confounder of
(PC = 0.50).
Number Needed to Treat (NNT). The NNT estimated by
using the pooled OR from the meta-analysis and based on the
mortality of CAP being around 10% at 30 days would be 73, (95%
CI: 48–158) [1].
Discussion
In this rigorously conducted systemic review and meta-analysis,
we observed that statins use is associated with a beneficial effect in
both the prevention and treatment of CAP. This association
constitutes very low quality evidence as per the GRADE
framework [51]. Factors that negatively influence the quality of
the evidence include the observational design, presence of
significant heterogeneity, and evidence of publication bias.
Although the effect estimates imply that statins lower the odds of
both developing CAP and death related to CAP, we found that the
effect estimates were influenced by other sources of bias besides the
ones adjusted for in the individual studies. We were able to identify
publication bias in the treatment group as opposed to Chopra and
colleagues [49] and adjusted for it by a novel regression method.
We found that around half of the apparent beneficial effect of
statins could be attributed to publication bias.
Our analysis is in agreement with some recently published
systematic reviews, but does have some important differences [48–
49]. First, our meta-analysis did not find any publication bias in
the prevention group to evaluate the role of statins in the
development of pneumonia. Second, in contrast to the study by
Chopra et al [49] we used meta-regression to explore sources of
heterogeneity, examined the effect of publication bias using
contour-enhanced funnel plot [59] and used a novel regression-
based method to adjust the pooled estimate for publication bias.
Third, we examined the potential effect of a residual confounding
on the observed association using the rule-out approach. We used
the GRADE framework to interpret the findings and draw
conclusions [51]. The Cochrane Collaboration has adopted the
principles of the GRADE system for evaluating the quality of
evidence for outcomes reported in systematic reviews [51].
The association between statins use and infection risk and
outcomes continues to be controversial. While several systematic
reviews of observational studies support this association [27,29], a
recent meta-analysis of RCTs [50] failed to prove a beneficial role
of statins in the prevention of infection in a pooled analysis of
eligible trials. This study was limited by the lack of reporting of
infection-related events in the majority of statin trials. In addition,
the majority of included trials did not describe the type of infection
in the cohort [50]. On the other hand, a recent open-label
controlled trial showed pravastatin to have a favorable outcome on
the frequency of development of ventilator associated pneumonia
(VAP) and associated overall mortality in statin-naı¨ve patients in
the ICU on mechanical ventilation [66]. These beneficial effects
were found in the sub-group of patients who were more critically
ill.
Our meta-analysis has several strengths. It was focused on CAP
and thus reduced the variability in the study populations with
panoply of infections. We also supplemented our analysis with
novel approaches to adjust for publication bias and unmeasured
confounders. We tried to quantify the effects of other sources of
bias in order to secure robust conclusions. All included studies
were population-based and the majority were multi-center studies;
Figure 2. Forest plot of prevention group (left panel) and treatment group (right panel) in the meta-analysis with random effects
model. Estimated odds ratios (OR) for the association of (statin use vs. non-use) and development of Pneumonia; CI- indicates Confidence Interval.
doi:10.1371/journal.pone.0052929.g002
Role of Statins in Management of Pneumonia
PLOS ONE | www.plosone.org 5 January 2013 | Volume 8 | Issue 1 | e52929
thus, the results have applicability to the general population. We
also calculated the NNT so as to measure the effectiveness of
statins in the general population.
There are limitations to our work. First, observational studies
are subject to inherent limitations in the study design leading to
unmeasured differences in the study population and unmeasured
confounders despite all possible adjustments. We have used a
novel approach to address the concern of unmeasured confound-
ing. This approach has been previously applied to address the issue
of statins and mortality in bacterial infections [29]. Second, use of
administrative records for classification of pneumonia could lead
to case ascertainment bias of CAP [33]. Third, the use of statins
was based on electronic and prescription records, rather than by
actual use by the patient. Fourth, the results may have been
affected by the ‘‘healthy user effect’’ [41,44,67] or even selective
underuse of statins in high risk groups [30]. However, we tried to
adjust for any unmeasured confounders affecting the pooled effect
estimate. Fifth, there is presence of publication bias in the
treatment group; we have tried to use a novel regression method to
adjust the pooled effect-estimate secondary to publication bias.
Lastly, there was substantial amount of heterogeneity in the
included studies. We used a random-effects model to minimize
heterogeneity. Some likely sources of heterogeneity were investi-
gated by means of a meta-regression, but were not to be found
significant. There are many patient level parameters which may
have led to substantial heterogeneity – time to antibiotic delivery,
place of care i.e. floor versus the ICU, frailty, nursing home status
and time duration from the index episode of pneumonia to
mortality. Investigating these variables is only possible with
individual patient data meta-analysis. Moreover, the heterogeneity
would mainly have an effect on the magnitude of the pooled
estimate rather than its direction (the effect-estimates of 7 out of 8
prevention studies and 12 out of 13 treatment studies support a
protective association).
Given the potential benefit of statins, and relatively low
speculated NNT, a dedicated RCT is warranted to further
examine their role in CAP prevention and treatment. To be
feasible, future RCTs have to focus on high risk groups for CAP or
Figure 3. Influence of a hypothetical confounder present in 20% (Left side, both panels) and 50% (Right side, both panels) of the
study population, unaccounted for in the adjustments already performed in the individual studies (Prevention group – top panel;
Treatment group – bottom panel). The graphs indicate what combinations of OREC and RRCD that would be necessary for the confounder to
fully account for the observed association between, (1) Statin use and development of pneumonia (ARR= 0.85)in the prevention group and; (2) Statin
use and mortality associated with pneumonia before (ARR= 0.70; Solid Line) and after (ARR= 0.86; Dashed Line) adjustment for publication bias) in
the treatment group. Abbreviations: OREC, odds ratio of exposure to the confounder in statin non-users vs. statin users; RRCD, relative risk of development
of pneumonia in individuals exposed to the confounder vs. non-exposed.
doi:10.1371/journal.pone.0052929.g003
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mortality from CAP such as the elderly, the immunocompromised
host or patients with significant co-morbid status. Performing an
RCT for this patient population will require a relatively small
sample size of patients to be enrolled as opposed to mega large
trials needed to study statins role in the general population.
Presently, because of the low quality of evidence available in the
favor of use of statins, we do not recommend initiating statins in
patients admitted with suspected CAP. We do suggest, however,
continuing pre-admission statins in patients admitted with
pneumonia.
Conclusions
Our meta-analysis reveals an association between statins and
the risk and mortality of CAP. However, the results constitute very
low quality evidence as per the GRADE framework due to
observational study design, heterogeneity and publication bias.
Given the biological plausibility of our findings and the high
burden and mortality of CAP, randomized, placebo-controlled
trials are warranted to further define the utility of statins in CAP,
especially in select high risk groups.
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